• 1
    Wheeler AP, Bernard GR. Treating patients with severe sepsis. NEJM. 1999; 340: 207214.
  • 2
    Levi M, Cate H ten. Disseminated intravascular coagulation. NEJM. 1999; 341: 586592.
  • 3
    Levi M. Disseminated intravascular coagulation. Crit Core Med. 2007; 35: 21912195.
  • 4
    Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Throm Haemost. 2001; 27: 593604.
  • 5
    Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haema-to. 2009; 22: 129136.
  • 6
    Sood, SL. Cancer-associated thrombosis. Curr Opin Hematol. 2009; 16: 378385.
  • 7
    Levi M. The coagulant response in sepsis. Clin Chest Med. 2008; 29: 627642.
  • 8
    Ogura H, Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock. 2007; 4: 411417.
  • 9
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub J, Garber GE, Helterbrand JD, Ely W, et al., for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis.
  • 10
    Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004; 2: 19241933.
  • 11
    Kushimoto S, Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Iba T, Ueyama M, Eguchi Y, Otomo Y, et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma. Thromb Haemost. 2008; 100: 10991105.
  • 12
    Bone RC. Gram positive organisms and sepsis. Arch Intern Med. 1994; 154: 2634.
  • 13
    Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinov V, Zakyn-thinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med. 2000; 28:451457.
  • 14
    Watson SP. Collagen receptor signaling in platelets and megakaryocytes. Thromb Haemost. 1999; 82:365376.
  • 15
    Levi M. Platelets in sepsis. Hematology. 2005; 10(Suppl. 1): 129131.
  • 16
    Lane DA, Phillippou H, Huntington JA. Directing thrombin. Blood. 2005; 106: 26052612.
  • 17
    Furie B, Furie BC. Mechanisms of thrombus formation. NEJM. 2008; 359: 938949.
  • 18
    Davizon P, Munday AD, Lopez JA. Tissue factor, lipid rafts, and microparticles. Semin Thromb Hemost. 2010; 36: 857864.
  • 19
    Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14 a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990; 249: 14311433.
  • 20
    Luyendyk JP, Schabbauer GA, Tencati M, Holscher T, Pawlinski R, Mackman N. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes(macrophages. J Immunol. 2008; 180: 42184226.
  • 21
    Popescu NI, Lupu C, Lupu F. Extracellular protein disulfide isomerase regulates coagulation on endothelial cells through modulation of phosphatidylserine exposure. Blood. 2010; 116: 9931001.
  • 22
    Osterud B and Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost. 2001; 27: 605617.
  • 23
    Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989; 134: 10871097.
  • 24
    Franco RF, de Jonge E, Dekkers PEP, Timmerman JJ, Speck CA, van Deventer SJH, van Deur-sen P, van Kerkhoof L, van Gemen B, Cate H ten, et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood. 2000; 96: 554559.
  • 25
    Pawlinski R, Wang J-G, Owens III AP, Williams J, Antoniak S, Tencati M, Luther T, Rowley JW, Low EN, Weyrich AS, et al. Hematopoetic and nonhematopoetic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood. 2010; 116: 806814.
  • 26
    Levi M, Cate H ten, Bauer KA, van der Poll T, Edgington TS, Büller HR, van Deventer SJH, Hack CE, Cate JW ten, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994; 93: 114120.
  • 27
    Taylor, Jr., FB, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991; 33: 127134.
  • 28
    Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med. 2001; 29(Suppl): S90S94.
  • 29
    Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992; 101: 816823.
  • 30
    Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood. 1996; 88:881886.
  • 31
    Mann HJ, Short MA, Schlichting DE. Protein C in critical illness. Am J Health Syst Pharm. 2009; 66: 10891096.
  • 32
    Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost. 1996; 75: 902907.
  • 33
    Maroney SA, Ellery PE, Mast AE. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res. 2010; 125(Suppl. 1): S52S56.
  • 34
    Basavaraj MG, Gruber FX, Applebom HI Sovershaev, Osterud B, Peterson LC, Hansen J-B. The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes. Thromb Res. 2010; 126: 418425.
  • 35
    Taylor FB, Jr., Peer GT, Lockhart MS, Ferrell G, Esmon CT. Blood. 2001; 97: 16851688.
  • 36
    Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006; 32(Suppl. 1): 4960.
  • 37
    Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004; 114: 321327.
  • 38
    Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa DJ, Kurosawa S. Inflammation, sepsis, and coagulation. Haematologica. 1999; 84: 254259.
  • 39
    Levi M, Dorffler-Melly J, Reitsma PH, Buller H, Florquin S, van der Poll T, Carmeliet P. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood. 2003; 101: 48234827.
  • 40
    Toltl LJ, Austin RC, Liaw PC. Activated protein C modulates inflammation, apoptosis, and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes. J Thromb Haemost. 2011; 9: 582592.
  • 41
    Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost. 2008; 34: 742746.
  • 42
    Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost. 1998; 24: 6169.
  • 43
    Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, Holschermann H. Antithrombin III inhibits nuclear factor kB activation in human monocytes and vascular endothelial cells. Blood. 2002; 99: 40154020.
  • 44
    Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care. 2006; 10: 209217.
  • 45
    Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost. 1996; 75: 224228.
  • 46
    Feistritzer C, Wiedermann CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther. 2007; 7: 855870.
  • 47
    Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas. 2008; 61: 122131.
  • 48
    van der Poll T, Levi M, Hack CE, Cate H ten, van Deventer SJ, Eerenberg AJ, deGroot ER, Jansen J, Gallati H, Buller HR, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 1994; 179: 12531259.
  • 49
    Mileno MD, Margolis NH, Clark BD, Dinarello CA, Burke JF, Gelfand JA. Coagulation of whole blood stimulates interleukin-1 beta gene expression. J Infect Dis. 1995; 172: 308311.
  • 50
    Van der Poll T, De Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost. 2001; 27: 639651.
  • 51
    Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000; 117: 11621172.
  • 52
    Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res. 2006; 12: 151170.
  • 53
    Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. NEJM. 1989; 320: 11651172.
  • 54
    Gando S, Kameue T, Nanzaki S, Nakanishi Y. Massive fibrin formation with consecutive impairment of fibrinolysis in patients with out-of-hospital cardiac arrest. Thromb Haemost. 1997; 77: 278282.
  • 55
    Pinsky DJ, Liao H, Lawson CA, Yan SF, Chen J, Carmeliet P, Loskutoff DJ, Stern DM. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest. 1998; 102:919928.
  • 56
    Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009; 145: 2433.
  • 57
    Kim SY, Kim J-E, Kyung H, Han K-S, Toh CH. Accuracy of platelet counting by automated hematologic analyzers in acute leukemia and disseminated intravascular coagulation: potential effects of platelet activation. Am J Clin Pathol. 2010; 134: 634647.
  • 58
    Park YA, Waldrum MR, Marques MB. Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. Am J Clin Pathol. 2010; 133: 460465.
  • 59
    Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, Marth JD. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008; 14: 648655.
  • 60
    Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997; 103: 114120.
  • 61
    Taylor FB, Jr., Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. On behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost. 2001; 86: 13271330.
  • 62
    Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective Validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004; 32: 24162421.
  • 63
    Toh CH, Hoots WK; On behalf of the SCC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the scientific and standardization committee on disseminated intravascular coagulation of the Internal Society of Thrombosis and Haemostasis. A 5-year review. J Thromb Haemost. 2007; 5: 604606.
  • 64
    Voves C, Wuillemin WA, Zeerleder S. International Society of Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Tibrinolysis. 2006; 17: 445451.
  • 65
    Wada H, Gabazza EC, Asakura H, Koike K, Okamoto K, Maruyama I, Shiku H, Nobori T. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for Overt DIC. Am J Hematol. 2003; 74: 1722.
  • 66
    Gando S, Wada H, Asakura H, Iba T, Eguchi Y, Okamoto K, Ohtomo Y, Kawasugi K, Koga S, Koseki K, et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost. 2005; 11: 7176.
  • 67
    Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, et al.; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006; 34: 625631.
  • 68
    Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, et al.; Japanese Society of Thrombosis Hemostasis(DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010; 125: 611.
  • 69
    Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood. 1982; 60: 284287.
  • 70
    Pernerstorfer T, Hollenstein U, Hansen J, KnechteIsdorfer M, Stohlawetz P, Graninger W, Eich-ler HG, Speiser W, Jilma B. Heparin blunts endotoxin-induced coagulation activation. Circulation. 1999; 100:24852490.
  • 71
    Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, et al. Prophylactic heparin I patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007; 176: 483490.
  • 72
    Franchini M, Mantazo F, Salvagno GL, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007; 18: 589593.
  • 73
    Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993; 269: 18291835.
  • 74
    Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics—an update. Eur J Pharmacol. 2008; 579: 112.
  • 75
    Package insert, Xigris. Eli Lilly and Company, Indianapolis, Indiana, USA. Updated 10/2008. Accessed on 11/08/10 at
  • 76
    Taylor FB, Jr., Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987; 79: 918925.
  • 77
    Hartman DL, Bernard GR, Helterbrand JD, Yan SB, Fisher CJ. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med. 1998; 24(Suppl. 1): S77. Abstract.
  • 78
    Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson 3rd G, Bernard GR, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003; 3: 834840.
  • 79
    Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, et al.; Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. 2003; 29: 894903.
  • 80
    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, et al.; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. NEJM. 2005; 353: 13321341.
  • 81
    Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care. 2009; 13: R103R116.
  • 82
    Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood. 1997; 89: 43934401.
  • 83
    Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000; 95: 11171123.
  • 84
    Taylor FB, Jr., Emerson TEJ, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock. 1988; 26: 227235.
  • 85
    Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Renzes I, Kubler A, et al.; For the KyberSept Trial Study Group. Caring for the critically ill patient. High dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001; 286: 18691878.
  • 86
    Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006; 4: 9097.
  • 87
    Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmaco Ther. 2006; 79: 2334.
  • 88
    Lavrentieva A, Kontakiotis T, Bitzani M, Parlapani A, Thomareis O, Scourtis H, Tsotsolis N, La-zaridis L, Giala MA. The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost. 2008; 100: 286290.
  • 89
    Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 2000; 28(Suppl. 9): S31S33.
  • 90
    Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FBJ, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993; 91: 28502856.
  • 91
    Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al.; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290: 238247.
  • 92
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; For the Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. NEJM. 2001; 345: 13681377.